(Q39559479)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Peter Vickerman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Ali Judd

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Vickerman P

1

1 reference

13 September 2017

Judd A

3

1 reference

13 September 2017

language of work or name

English

0 references

publication date

11 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Epidemiology

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

396-405

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17218325%20AND%20SRC:MED&resulttype=core&format=json

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Natural course of acute hepatitis C: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

The burden of hepatitis C in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Effectiveness of needle-exchange programmes for prevention of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Prevalence of hepatitis C among injectors in Scotland 1989-2000: declining trends among young injectors halt in the late 1990s.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Global burden of disease (GBD) for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Hepatitis C virus among self declared non-injecting sexual partners of injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Methods of transmission of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Cross-genotype immunity to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Protection against persistence of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Cell-mediated immunity and the outcome of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Indications of immune protection from hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Full or partial seroreversion in patients infected by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Association between injection practices and duration of injection among recently initiated injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Transmission of hepatitis C virus: rates, routes, and cofactors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Modelling the spread of HIV in social networks of injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Efficacy of HCV core antigen detection during the preseroconversion period

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Neutralizing antibody response during acute and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Detection of antibodies against hepatitis C virus in saliva: a marker of viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276

Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYL276